1,465 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Bank of New Hampshire

Bank of New Hampshire acquired a new position in Boston Scientific Co. (NYSE:BSX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,465 shares of the medical equipment provider’s stock, valued at approximately $113,000.

Several other large investors also recently modified their holdings of the company. Pinnacle Associates Ltd. grew its holdings in shares of Boston Scientific by 2.0% in the first quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after acquiring an additional 148 shares during the period. KCM Investment Advisors LLC grew its holdings in shares of Boston Scientific by 1.7% in the first quarter. KCM Investment Advisors LLC now owns 9,225 shares of the medical equipment provider’s stock worth $632,000 after acquiring an additional 150 shares during the period. Hazlett Burt & Watson Inc. grew its holdings in shares of Boston Scientific by 24.0% in the first quarter. Hazlett Burt & Watson Inc. now owns 826 shares of the medical equipment provider’s stock worth $57,000 after acquiring an additional 160 shares during the period. BSW Wealth Partners grew its holdings in Boston Scientific by 2.3% during the fourth quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock valued at $428,000 after purchasing an additional 165 shares during the period. Finally, Allstate Corp grew its holdings in Boston Scientific by 2.9% during the fourth quarter. Allstate Corp now owns 5,938 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 165 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on BSX shares. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a report on Thursday, July 25th. Citigroup boosted their price target on Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Robert W. Baird boosted their price target on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Raymond James boosted their price target on Boston Scientific from $85.00 to $91.00 and gave the company a “strong-buy” rating in a report on Thursday, July 25th. Finally, Needham & Company LLC boosted their price target on Boston Scientific from $82.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $84.76.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at approximately $2,978,734.56. The disclosure for this sale can be found here. Insiders have sold a total of 51,837 shares of company stock worth $3,884,563 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX traded down $0.66 during mid-day trading on Friday, reaching $74.50. The stock had a trading volume of 5,500,518 shares, compared to its average volume of 6,960,298. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The company has a market cap of $109.30 billion, a P/E ratio of 62.61, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $79.43. The business’s 50 day moving average price is $76.42 and its 200 day moving average price is $70.91.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion for the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 earnings per share. Research analysts expect that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.